FDA Peptide Therapy Regulations and What They Mean for Your Marketing

FDA regulation of peptide therapy is one of the most misunderstood topics in the industry. Clinic owners often assume the rules are either non-existent or so strict that marketing is impossible. Neither is true. This post breaks down what the FDA actually says about peptides, what it means for your marketing, and how to structure messaging that stays clearly inside the rules.

Peptides fall into three FDA categories. First, FDA-approved drugs like semaglutide and tirzepatide, which have specific approved indications. Second, compoundable peptides prepared by 503A or 503B pharmacies under specific conditions. Third, non-compoundable research peptides that should not be used clinically. Each category has different marketing implications.

FDA-approved peptides can be marketed for their approved indications. Semaglutide can be marketed for chronic weight management and type 2 diabetes. Off-label marketing is a gray area and generally should be avoided in ads even when off-label prescribing is legal. Stick to approved indications in all ad copy to minimize regulatory risk.

Compounded peptides can be prescribed clinically but cannot be marketed with disease treatment claims. Marketing compounded peptides requires careful language that describes the therapy and the provider process without claiming specific medical outcomes. The FDA has taken action against clinics that market compounded peptides as if they were approved drugs.

The FDA maintains a list of bulk ingredients that 503A pharmacies can use in compounding. Some peptides are on the list, some are not, and the list changes over time. Clinic owners should work with compounding pharmacies that only use approved bulk ingredients and should update marketing whenever the list changes.

FDA rules mean peptide therapy marketing has to focus on the clinic, the provider, and the process rather than on outcome claims. Great peptide marketing describes the consultation experience, the personalized protocol approach, the pharmaceutical-grade sourcing, the clinical monitoring, and the provider credentials. This kind of content-forward marketing outperforms hype-based marketing in conversion anyway, so compliance and performance usually align.

Avoid miracle language, specific outcome promises, testimonial-heavy ads that imply guaranteed results, and any copy that positions compounded peptides as FDA-approved for specific conditions. These are the most common triggers for FDA warning letters and ad platform rejections.